DGMed ECT Portal
TR EN

Clearance and Assessment Documents

Device clearances, health technology assessments, trial registration records and manufacturer instructions for use. None of these is a peer-reviewed journal publication: they do not produce evidence but show how evidence is assessed and under what frame a device is on the market.

59document records
4document types
2006–2026document span

Who Cleared What, and When

The 14 FDA 510(k) documents in the archive belong to 6 manufacturers. The 510(k) route shows that a device is substantially equivalent to one already on the market; it does not show that its efficacy was demonstrated.

ManufacturerDocumentsSpan
AngioDynamics52011–2026
Galvanize Therapeutics32022–2026
Oncobionics32006–2008
US Medical Innovations12024–2024
Surgnova Healthcare Technologies12024–2024
Zhejiang Curaway Medical Technology12023–2023

How many assessments each body published

The 25 health technology assessments come from 7 bodies. The existence of a report does not mean a favourable decision: some of the documents here are suspension and consultation decisions.

BodyDocuments
NICE9
G-BA8
AIHTA2
IQWiG2
LBI-HTA2
Heidelberg University Hospital1
ACIS_avalia-t1

The records on this page are not included in the portal's publication counts. The oncology corpus and the extended electroporation corpus count electroporation publications only; the documents here are kept in the source archive as context and are reported with their own figures.

The Full Set of Documents

That a device is cleared does not mean its efficacy has been demonstrated; the 510(k) route shows substantial equivalence to a device already on the market. Likewise the existence of an HTA report does not mean a favourable decision: some of the documents here are suspension and consultation decisions.

FDA 510(k) Clearances

Premarket notifications issued by the US Food and Drug Administration for electroporation devices. A clearance is not a publication; it records when, for which manufacturer and under which description a device was cleared.

YearBodyDocumentDocument reference
2026Galvanize TherapeuticsAliya® EX System; Aliya® EX Generator; Aliya® Needle; Aliya®K253826
2026AngioDynamicsNanoKnife Generator (H78720300351US0)K253198
2024US Medical InnovationsCanady Helios Cold Plasma™ XL-1000CP™ Ablation System (XL-10K240297
2024Surgnova Healthcare TechnologiesElectroporation System (N3000)K240376
2024Galvanize TherapeuticsINUMI™ Flex NeedleK233884
2024AngioDynamicsNanoKnife Generator (H78720300301US0); NanoKnife Single ElecK242687
2023Zhejiang Curaway Medical TechnologyIrreversible Electroporation Ablation Generator, IrreversiblK222001
2022Galvanize TherapeuticsAliya(TM) System, Aliya(TM) Generator, Aliya(TM) Needle, AliK212871
2019AngioDynamicsNanoKnife SystemK183385
2015AngioDynamicsNanoKnife SystemK150089
2011AngioDynamicsNANOKNIFE SYSTEMK102329
2008OncobionicsONCOBIONIC SYSTEMK080376
2008OncobionicsONCOBIONIC SYSTEM WITH 6 PROBE OUTPUTK080202
2006OncobionicsONCOBIONIC SYSTEMK060054

Health Technology Assessments

Assessment reports published by bodies such as NICE, G-BA, IQWiG, AIHTA and LBI-HTA. They show how an indication is assessed at country level; they interpret evidence rather than produce it.

YearBodyDocumentDocument reference
2025G-BAIRE in chronic bronchitis, supporting reasons for extending the suspensionBVh-20-003, TrG
2025G-BAIRE in chronic bronchitis, extension of the suspensionBVh-20-003
2025G-BAIRE in chronic bronchitis, initiation of the consultation procedureBVh-20-003
2024AIHTASBRT, proton therapy and IRE in localised prostate cancerUpdate 2024
2024AIHTABleomycin electrosclerotherapy (BEST) in vascular anomalies, systematic reviewDSD 137
2023NICEIRE in prostate cancerHealthTech htg688, formerly IPG572-IPG768
2021IQWiGIRE in chronic bronchitis, H20-03 addendum–
2021IQWiGIRE in chronic bronchitis, SGB V §137h assessment–
2021G-BAIRE in chronic bronchitis, notice initiating the Erprobung procedureBVh-20-003, BAnz
2021G-BAIRE in chronic bronchitis, suspension of the Erprobung directiveBVh-20-003
2021G-BAIRE in chronic bronchitis, §137h decision BVh-20-003–
2020G-BAIRE in chronic bronchitis, first §137h assessment decisionBAh-19-003, BAnz
2020G-BAIRE in chronic bronchitis, supporting reasons for the §137h decisionBAh-19-003, TrG
2019LBI-HTAIRE in liver and pancreatic cancer–
2019Heidelberg University HospitalIRE in chronic bronchitis, G-BA §137h information notice52 pp.
2019NICEIRE in primary liver cancerHealthTech htg532, formerly IPG444-IPG664
2018LBI-HTASBRT, proton therapy and IRE in localised prostate cancer–
2017NICEIRE in pancreatic cancerHealthTech htg437, formerly IPG579-IPG442
2014ACIS_avalia-tIRE in pancreatic and liver cancer–
2014NICEElectrochemotherapy in primary basal and squamous cell carcinomaHealthTech htg333, formerly IPG478
2014NICEElectrochemotherapy in primary basal and squamous cell carcinomaIPG478 first PDF version, 8 pp.
2013NICEIRE in renal cancerHealthTech htg303, formerly IPG443
2013NICEElectrochemotherapy in skin metastasesHealthTech htg305, formerly IPG446
2013NICEIRE in liver metastasesHealthTech htg304, formerly IPG445
2013NICEIRE in primary lung cancer and lung metastasesHealthTech htg302, formerly IPG441

Trial Registration Records

Trial registration records taken from the ISRCTN registry. The machine-readable export of the registry is processed separately on the Clinical Trials page; the documents here are the registry's own PDF.

YearBodyDocumentDocument reference
2025ISRCTNIntratumoural gene electrotransfer in skin cancer (n=9)ISRCTN15479959
2025ISRCTNFeasibility of an IRE clinical study (n=50)ISRCTN14986389
2023ISRCTNCT-navigated needle placement in IRE (n=20)ISRCTN55383115
2022ISRCTNEffectiveness of ECT in head and neck cancer (n=50)ISRCTN37372189
2022ISRCTNOptimisation of bleomycin concentration in ECT (n=80)ISRCTN74054653
2022ISRCTNWT1 DNA vaccine in haematological malignancies, intramuscular electroporation (n=184)ISRCTN62678383
2020ISRCTNECT in basal cell carcinoma (n=100)ISRCTN14633165
2020ISRCTNPercutaneous ECT in soft tissue tumours (n=30)ISRCTN11667954
2019ISRCTNECT in cutaneous metastases of breast cancer (n=404)ISRCTN56719146
2017ISRCTNHIVIS07, plasmid DNA-MVA with electroporation (n=48)ISRCTN60284968
2016ISRCTNEURECA, European research project on ECT in head and neck cancer (n=120)ISRCTN78463063

Manufacturer Instructions for Use

Instructions for use, technical sheets and brochures published by device manufacturers. These are the manufacturer's own statements, not independent assessments.

YearBodyDocumentDocument reference
2026BIONMED TechnologiesSENNEX Technical Data and Certification Data2026-08-13
2024BIONMED TechnologiesSENNEX EC Declaration of Conformity2024-05-15
2024BIONMED TechnologiesSENNEX Tumor System Instructions for UseV1.16.9 EN
2022Galvanize TherapeuticsAliya System 2.5 Instructions for UseLBL-00054 Rev H
–IGEACliniporator EPS02 Instructions for Use75 pp., ManualsLib
–IGEACliniporator EPS02 Technical SheetRev 1.1
–IGEACliniporator brochureEN
–AngioDynamicsNanoKnife Instructions for Use96 pp., ManualsLib
–AngioDynamicsNanoKnife brochuredistributor document